AGL vs VRDN: Which Stock Is the Better Buy?
agilon health, inc. and Viridian Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AGL vs VRDN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| agilon health, inc. (AGL) | Viridian Therapeutics, Inc. (VRDN) | |
|---|---|---|
| Market cap | $1.8B | $1.8B |
| Revenue (latest FY) | $5.93B | $70.85M |
| Net income (latest FY) | $-391.35M | $-342.60M |
| Revenue growth (5y CAGR) | 37.2% | 132.2% |
| Net margin | -6.6% | -483.6% |
| Return on equity | -308.8% | -47.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full AGL vs VRDN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AGL's full financials → Open VRDN's full financials →More comparisons
Frequently asked questions
Which is bigger, AGL or VRDN?
Viridian Therapeutics, Inc. is larger by market capitalization — $1.8B versus $1.8B.
Which grows faster, AGL or VRDN?
Over the last five fiscal years, Viridian Therapeutics, Inc. grew revenue faster — 132.2%/yr versus 37.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
AGL fundamentals → · VRDN fundamentals → · All 1,500+ companies → · Free screener →